1 **Design of efficient artificial enzymes using crystallographically-enhanced**

2 **conformational sampling**

3

4 **Rojo V. Rakotoharisoa,[1,2] Behnoush Seifinoferest,[3] Niayesh Zarifi,[1,2] Jack D.M. Miller,[1,2]**

5 **Joshua M. Rodriguez,[3] Michael C. Thompson,[3,*] Roberto A. Chica[1,2,*]**

6

7 [1] Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario,

8 Canada, K1N 6N5

9 [2] Center for Catalysis Research and Innovation, University of Ottawa, Ottawa, Ontario, Canada,

10 K1N 6N5

11 [3] Department of Chemistry and Biochemistry, University of California Merced, Merced,

12 California 95343, United States

13

14 [*] To whom correspondence should be addressed:

15 Roberto A. Chica, Email: rchica@uottawa.ca

16 Michael C. Thompson, Email: mthompson30@ucmerced.edu

17

18

19 **Keywords**

20 De novo enzyme design; Kemp eliminases; biocatalysis; directed evolution; ensemble

21 refinement; X-ray crystallography

22

23 **Abstract**

24 The ability to create efficient artificial enzymes for any chemical reaction is of great interest. Here,

25 we describe a computational design method for increasing catalytic efficiency of *de novo* enzymes

26 to a level comparable to their natural counterparts without relying on directed evolution. Using

27 structural ensembles generated from dynamics-based refinement against X-ray diffraction data

28 collected from crystals of Kemp eliminases HG3 (k_{cat}/K_M 125 $M^{-1}\,s^{-1}$) and KE70 (k_{cat}/K_M 57 M^{-1}

29 s^{-1}), we design from each enzyme ≤10 sequences predicted to catalyze this reaction more

30 efficiently. The most active designs display k_{cat}/K_M values improved by 100–250-fold, comparable

31 to mutants obtained after screening thousands of variants in multiple rounds of directed evolution.

32 Crystal structures show excellent agreement with computational models. Our work shows how

33 computational design can generate efficient artificial enzymes by exploiting the true

34 conformational ensemble to more effectively stabilize the transition state.

35

36 **Main text**

37   The ability to create efficient artificial enzymes for any desired chemical reaction is of

38 great interest as it would open the door to a broad range of applications in industry and medicine.

39 Algorithms for *de novo* enzyme design[1,2] can be used to create artificial enzymes for reactions for

40 which no naturally occurring enzyme is known. While this computational design process has been

41 used to produce *de novo* enzymes for various model organic transformations[3-7], downstream

42 directed evolution has been necessary to convert these enzyme prototypes into catalysts as efficient

43 as their natural counterparts[8-13]. However, directed evolution is costly, time-consuming and

44 impractical for many enzymatic reactions of interest for which high-throughput screening assays

45 are unavailable. Therefore, a computational design procedure to enhance catalytic efficiency of *de*

46 *novo* enzymes would be beneficial as it could bypass directed evolution and accelerate the creation

47 of efficient artificial enzymes.

48   Structural analyses of high activity variants evolved from *de novo* enzymes revealed

49 several mechanisms by which catalytic function can be augmented. These mechanisms include

50 optimization of hydrogen-bond geometries between catalytic residues and the transition state[8],

51 enhancement of active-site complementarity to the transition state[8,9,14], improvement of active-site

52 preorganization[14], and enrichment of catalytically competent substates in the conformational

53 ensemble[15-17]. These structural effects are challenging to design using current enzyme design

54 protocols[3,7,9] because they are not sufficiently precise[8] and do not consider the dynamic nature of

55 enzyme structures[15]. Recently, new methodologies have been developed that take advantage of the

56 spatiotemporal averaging inherent to X-ray crystallography – crystallographic data represent

57 billions of crystallized molecules that are all sampling different conformations during data

58 collection – to model the conformational ensembles of proteins with high fidelity[18,19]. New design

3

59   strategies that could exploit this experimental information should facilitate the design of efficient

60   artificial enzymes by enabling accurate modeling of catalytically productive conformational

61   substates.

62   Here, we report a computational procedure for enhancing the catalytic efficiency of *de novo*

63   enzymes that exploits crystallographically-derived ensemble models for increased accuracy.

64   Starting from the non-cryogenic crystal structure of *de novo* Kemp eliminase HG3[7,14], we generate

65   a structural ensemble fitted to the diffraction data[18,20] and use it to design mutant sequences

66   predicted to efficiently catalyze the Kemp elimination. We filter these sequences using a variety

67   of structural criteria aiming to reproduce molecular mechanisms known to augment enzyme

68   catalysis, and experimentally characterize 10 sequences. The most active design displays a

69   catalytic efficiency improved by approximately 250-fold, a result comparable to those obtained by

70   seven rounds of directed evolution and screening of >7000 variants[8]. We solve crystal structures

71   of several high-activity variants, which show excellent agreement with the computational models

72   and confirm that catalytic efficiency is enhanced via the intended molecular mechanisms. We also

73   demonstrate the general applicability of our approach by applying it to an unrelated *de novo* Kemp

74   eliminase, KE70[3], which yields comparable results. Our work shows how ensemble-based design

75   can generate efficient artificial enzymes by exploiting information derived from X-ray

76   crystallography to identify productive substates for efficient catalysis.

77

78   **Results**

79   *Ensemble-based enzyme design*

80   To create efficient *de novo* enzymes without relying on iterative rounds of mutagenesis and

81   high-throughput screening, we implemented an ensemble-based computational enzyme design

4

82   pipeline that uses protein backbones generated by ensemble refinement of diffraction data[18] as

83   templates for design (Figure 1). Because the diffraction data and calculated electron density maps

84   are derived from crystals that contain billions of molecules, which are all sampling different

85   conformational states throughout data collection, the resulting ensemble models are expected to

86   represent the entire equilibrium conformational ensemble of the target protein fold[21]. Thus, we

87   postulated that performing crystallographic ensemble refinement on a low activity *de novo* enzyme

88   would allow sampling of conformational substates that can more accurately accommodate the

89   transition state and its interactions with catalytic residues than the single conformation modeled

90   using traditional refinement methods, thereby facilitating the design of improved active sites. To

91   test our hypothesis, we applied ensemble-based design to increase catalytic efficiency of the *de*

92   *novo* enzyme HG3[7] that catalyzes the Kemp elimination (Supplementary Figure 1a), a well-

93   established model organic transformation for benchmarking computational enzyme design

94   methods. We selected HG3 as a case study for three reasons. First, X-ray diffraction data collected

95   at non-cryogenic temperatures (277 K) were available[14], which is ideal for ensemble refinement

96   because cryocooling is known to narrow the conformational ensemble of crystallized proteins[22],

97   reducing the number of conformations that are represented in the ensemble-averaged data. Second,

98   these data were collected from crystals with a bound transition-state analogue that is resolved in

99   the electron density[14], allowing inclusion of the transition state in the ensemble models. Finally,

100   HG3 was subjected to an extensive directed evolution campaign that increased catalytic efficiency

101   by almost three orders of magnitude[8], allowing us to compare results with those from purely

102   experimental approaches.

103   We generated an ensemble of 84 backbone templates (Supplementary Table 1) from the

104   crystal structure of HG3 bound with the 6-nitrobenzotriazole (6NT, Supplementary Figure 1b)

105   transition-state analogue (PDB ID: 5RGA[14]) and used these structures for placement of four

106   theozymes containing an Asp residue as catalytic base, and either a Gln, Asn, Ser or Thr to act as

107   hydrogen-bond donor for stabilizing negative charge buildup on the phenolic oxygen at the

108   transition state (Figure 1a). We kept the base position fixed to that of HG3 (D127) but allowed the

109   algorithm to place the hydrogen-bond donor at multiple positions in the active site given that no

110   amino acid residue in HG3 forms this catalytic contact with 6NT[14]. We then repacked the active

111   site around the most stable theozyme placed on each backbone template by optimizing the identity

112   and side-chain conformation of neighbouring residues to maximize beneficial packing interactions

113   with the transition state, which has been shown to contribute to increased catalytic activity[8].

114   After repacking, we filtered designs using a series of structural metrics aiming to reproduce

115   mechanisms known to augment enzyme catalysis (Figure 1b, Supplementary Table 2). First, we

116   measured angles defining the hydrogen bond between D127 and the transition state for the top-

117   scoring design obtained on each backbone template, and selected sequences from the single

118   backbone template that gave the most stable design with angles that were closest to the optimal

119   geometries calculated for acetamide dimers[23] (Supplementary Figure 2, Supplementary Table 3).

120   The selected backbone, which we name bb05, yielded sequences that contain the Q50 hydrogen-

121   bond donor that emerged during evolution of HG3 and that is present in the highest activity variants

122   of this enzyme family[8]. Second, we evaluated active-site complementarity to the transition state

123   by calculating the solvent-accessible surface area of this ligand in the computational models

124   generated for 1000 sequences designed on backbone bb05. Only designs where ≥95% of the

125   transition state surface is buried were kept. Third, we evaluated active-site preorganization by

126   calculating the percentage of designed active-site residues that were predicted to adopt similar

127   rotamers in the absence and presence of the transition state, which we consider to be preorganized

128 for catalysis. Sequences whose active-sites were predicted to be >70% preorganized were kept.

129 We also eliminated sequences with calculated energies over 10 kcal mol^{-1} higher than that of an

130 HG3 single point mutant containing the D127/Q50 catalytic dyad, as well as those that contained

131 more than four methionines or more than one cysteine in the active site to avoid excessive

132 conformational heterogeneity and prevent formation of disulfide bonds, respectively. This filtering

133 process narrowed the original list of 1000 designs obtained from backbone bb05 down to 55

134 designs. A final filtering step consisting of a 20-ns molecular dynamics simulation was used to

135 identify designs that were enriched in catalytically-competent conformational substates, which we

136 define as snapshots that make the designed catalytic contacts (Supplementary Figure 3). This final

137 filtering resulted in nine sequences containing four or five mutations each (Table 1), which we

138 experimentally characterized.

139

140 *Kinetic characterization of designs*

141 All nine designs catalyzed the Kemp elimination (Supplementary Figure 4). The most

142 active of these variants, HG630, had a catalytic efficiency of $15,000 \pm 500$ M^{-1} s^{-1}, a value that is

143 120-fold higher than that of the starting template HG3 (Table 1). Furthermore, the three most active

144 designs (HG198, HG259 and HG630) were more catalytically efficient than the HG3.3b variant

145 obtained after three rounds of directed evolution and screening of >3000 mutants[8]. These designs

146 all contain the M84C mutation that was previously shown to increase catalytic efficiency by one

147 order of magnitude when combined with K50Q to yield the HG3-K50Q/M84C double mutant[15]

148 (Table 1). Analysis of mutant sequences suggested that introduction of the Q90F mutation into

149 HG630 would further enhance its catalytic efficiency, as it doubles k_{cat}/K_M when introduced into

150 HG57 to yield HG44. Introduction of this mutation into HG630 resulted in a hexamutant (HG649)

7

151   that is 256-fold more catalytically efficient than HG3 (k_{cat}/K_M = 32,000 ± 3000 M^{-1} s^{-1}) and more

152   active than HG3.7, a variant found after seven rounds of directed evolution involving the screening

153   of >7000 mutants[8] (Table 1, Figure 2a). HG649 shares a majority of its mutation sites with HG3.7

154   but the combination of specific amino-acid substitutions is distinct, with only two mutations in

155   common (Figure 2b). These results demonstrate how ensemble-based enzyme design produces

156   similar activity increases as directed evolution but at a fraction of the experimental screening cost.

157   Interestingly, HG649 was one of the 55 designs that passed all filtering criteria except for the final

158   molecular dynamics analysis, which led to its elimination due to its low predicted catalytic

159   competency (Supplementary Figure 3). This false negative, along with the two false positives

160   (Table 1, HG378 and HG57), indicate that improvements are required to make the molecular

161   dynamics filtering more robust and suggests that other eliminated sequences may also display high

162   catalytic efficiency.

163

164   *Crystal structures*

165   To evaluate whether the catalytic efficiency of our designs was increased via the predicted

166   molecular mechanisms (Figure 1b), we solved room-temperature (280 K) X-ray crystal structures

167   of four of the most active designs (HG185, HG198, HG630 and HG649) in the presence and

168   absence of the 6NT transition-state analogue. We used room-temperature X-ray crystallography

169   for direct comparison with the HG3 non-cryogenic structure used to generate the ensemble and

170   because this method can reveal conformational heterogeneity in protein structures that would not

171   be visible at cryogenic temperatures, providing insights into the conformational ensemble that is

172   sampled by a protein[21,24]. Crystals of HG185, HG630, and HG649 were obtained in the absence

173   of 6NT, and soaked into solutions containing this molecule prior to X-ray data collection to obtain

174   the analogue-bound structures (Supplementary Table 4). These three enzyme variants all

175   crystallize in space group P 2_1 with two molecules in the asymmetric unit, roughly matching the

176   crystal form reported for HG3[14]. On the other hand, HG198 could only be crystallized in the

177   presence of 6NT, and its unbound structure was derived from serially soaking these crystals in

178   solutions lacking the transition-state analogue prior to data collection. In the presence of 6NT,

179   HG198 crystallizes in the low symmetry space group P 1 with three molecules in the asymmetric

180   unit, but removing the transition-state analogue via serial soaking transforms the crystals to space

181   group P 2_1 with a single molecule in the asymmetric unit. This unusual transformation of the crystal

182   system was consistent over multiple crystal specimens. All crystals diffracted at resolutions of

183   1.32–1.90 Å, which enabled us to create high-quality structural models (Supplementary Table 5).

184   All designs bound 6NT in the same catalytically productive pose (Figure 3a) as that

185   observed in HG3, in excellent agreement with the computational models generated by ensemble-

186   based design (Figure 4) but in stark contrast with those generated using the average crystal

187   structure (Supplementary Figure 5). In this pose, the acidic N–H bond of 6NT that mimics the

188   cleavable C–H bond of the substrate is located within hydrogen-bonding distance to the

189   carboxylate oxygen of D127, while the basic nitrogen atom corresponding to the phenolic oxygen

190   of the transition state forms a hydrogen bond with the N_ε atom of Q50, similar to what was

191   observed for evolved variant HG3.7[14]. By contrast, HG3 does not form this second hydrogen bond

192   because its K50 residue does not adopt a suitable side-chain conformation and instead it is a water

193   molecule that hydrogen-bonds to the basic nitrogen atom of 6NT. In all cases, angles defining the

194   hydrogen bond between D127 and the transition-state analogue were improved or within error

195   compared to HG3 (Supplementary Table 3). In contrast to all other enzymes, the 6NT transition-

196   state analogue of HG185 refined to an occupancy of approximately 60%, indicating that its crystal

9

197   comprises a mixture of enzyme molecules in their bound and unbound forms. Given that the

198   soaking procedure we used to generate crystals of HG185 bound to 6NT was identical to the one

199   used to soak isomorphous crystals of HG630 and HG649 (Supplementary Table 4), which yielded

200   6NT bound at 100% occupancy, it is likely that the lower occupancy of this ligand in HG185

201   reflects its weaker binding in the active site, in agreement with the enzyme's 6.5–14-fold lower

202   catalytic efficiency compared to HG630 and HG649 (Table 1). The lower occupancy of 6NT in

203   the HG185 structure is reflected by weaker electron density in the active site and the presence of

204   an alternate D127 rotamer that does not hydrogen-bond with the transition-state analogue (Figure

205   3a). Regardless, the active site of all designed variants is more complementary to the transition

206   state than that of HG3, as indicated by the lower solvent-accessible surface area for 6NT when

207   bound in the active site of these variants (Figure 3b).

208   Next, we evaluated active-site preorganization by comparing structures in the presence and

209   absence of bound 6NT. In HG3, the unbound form is never preorganized for catalysis as both W44

210   and M237 adopt conformations that would prevent productive binding of 6NT in the major or

211   minor conformations, respectively (Figure 3c). This is also the case for evolved variant HG3.7[14].

212   HG185 is also never preorganized in the unbound form because C21 exclusively adopts a rotamer

213   that would clash with 6NT. Furthermore, the D127 catalytic residue of HG185 adopts a low-

214   occupancy (7% and 14% for chains A and B, respectively), catalytically non-productive

215   conformation in the unbound form that cannot interact favorably with 6NT, likely contributing to

216   its inferior activity compared with the other variants. In contrast, active sites of higher activity

217   variants HG198, HG630 and HG649 are correctly preorganized for catalysis in a substantial

218   portion of the molecules in the crystal, with only M237 adopting a non-productive conformation

219   at 47–64% occupancy (Figure 3c). Overall, crystal structures confirmed that activity of designed

220   HG variants was increased by several of the mechanisms known to enhance enzyme catalysis and

221   that we aimed to reproduce using our filtering criteria.

222

223   *Enrichment of catalytically competent substates*

224   The ability of an enzyme to frequently sample productive substates in its conformational

225   ensemble is another important feature of efficient catalysis[15,17,25,26]. To evaluate this property for

226   our designs, we performed ensemble refinement of their 6NT-bound structures and evaluated the

227   proportion of ensemble members that make the designed catalytic contacts with the transition-state

228   analogue. We observed that in HG3, the hydrogen bond between the catalytic base and 6NT is

229   formed in 82% of ensemble members, and no interaction is observed between the ligand and K50

230   (Figure 3d). In HG185, interactions between 6NT and catalytic residues D127 and Q50 are present

231   in 45% and 65% of ensemble members, respectively, likely due to the lower occupancy of 6NT.

232   In the case of the most active variants HG198, HG630 and HG649, catalytic contacts to both D127

233   and Q50 are present in ≥95% of ensemble members, and their ensembles are less structurally

234   diverse than those of HG3 or HG185 (Figure 3d, Figure 5a, Supplementary Table 6). The higher

235   percentage of hydrogen bonds between 6NT and catalytic residues and narrower conformational

236   ensembles of high activity HG variants whose structures contain transition-state analogues at

237   100% occupancy confirm a higher population of catalytically-competent substates than in the

238   ensemble of HG3.

239   Having established that the conformational ensembles of efficient HG variants were

240   enriched in catalytically competent substates, we investigated whether the bb05 template that we

241   extracted from the HG3 ensemble and used as design template is a better approximation of the

242   transition-state ensemble than the HG3 crystal structure obtained by traditional refinement of a

243   single, major conformation. To do so, we calculated the pairwise backbone root-mean-square

244   deviations of designed active-site residues (Supplementary Table 7) between every member of the

245   HG variants' ensembles and bb05. Distributions of root-mean-square deviations show that the

246   bb05 active-site backbone is as or more structurally similar to the ensembles of the two most active

247   variants (HG630 and HG649) than to its own ensemble (Figure 5b, Supplementary Table 6). By

248   contrast, the HG3 crystal structure with bound 6NT is more similar to its own ensemble than to

249   those of all higher activity HG variants (Figure 5c, Supplementary Table 6). These results strongly

250   support our hypothesis that ensemble refinement performed on the crystal structure of a low

251   activity *de novo* enzyme allows sampling of catalytically-productive conformational substates for

252   more accurate accommodation of the transition state than the single crystal structure.

253

254   *KE70 designs*

255   To test the general applicability of our ensemble-based enzyme design method, we applied

256   it to another Kemp eliminase that was designed on a distinct protein scaffold. This enzyme, KE70,

257   contains a His/Asp dyad that acts as catalytic base and a Ser hydrogen-bond donor to stabilize the

258   phenolic oxygen of the transition state[3]. To allow direct comparison to our HG variants, we

259   designed variants using a theozyme comprising an Asp residue as catalytic base and a Gln as

260   hydrogen-bond donor. Starting from the available unbound cryogenic crystal structure of KE70

261   (PDB ID: 3NPV[10]), we generated an 84-member ensemble (Supplementary Table 1) and used it to

262   design variants predicted to efficiently catalyze the Kemp elimination using a similar protocol as

263   that used for HG variants but without the final filtering step involving molecular dynamics

264   (Methods). Three variants were selected for kinetic analysis, and these contain between 11 and 13

265   mutations (Supplementary Table 8), including the D16 and Q138 catalytic motif as well as two

266 insertions in active site loops (S20a and A240a) that we introduced after design to allow for

267 comparison with evolved KE70 variants that contain these insertions[10]. Two of the three tested

268 designs were active (Table 1, Supplementary Figure 6). The most active variant, KE703, displays

269 a k_{cat}/K_M of 2500 ± 300 M^{-1} s^{-1}, which is 44-fold higher than KE70 and approximately 17-fold

270 higher than that of a KE70 variant containing the two loop insertions (Table 1). To compare with

271 evolved KE70 variants that contain the His/Asp dyad as catalytic base, we introduced the D16H

272 and N45D mutations into KE703, generating the KE703b variant. This variant has a k_{cat}/K_M of

273 5500 ± 100 M^{-1} s^{-1}, which is approximately 100-fold higher than KE70 and two-fold higher than

274 that of the evolved variant R4 8/5A that was isolated after 4 rounds of directed evolution and

275 screening of approximately 4000 clones[10] (Figure 2c). KE703b shares a majority of its mutation

276 sites with R4 8/5A but its specific amino-acid substitutions are distinct, with only three mutations

277 in common (Figure 2d). These results confirm the general applicability of ensemble-based design

278 and its ability to generate artificial enzymes that are orders of magnitude more active than the

279 original *de novo* enzymes at a fraction of the experimental effort required by directed evolution.

280 Furthermore, our results show that ensemble-based design does not require an ensemble generated

281 from a crystal structure with a bound transition-state analogue to be successful, which is

282 advantageous given that such structures are less common than unbound ones.

283

Discussion

285 In this work, we used ensemble-based design to increase the catalytic efficiency of the HG3

286 and KE70 *de novo* Kemp eliminases by two orders of magnitude, yielding artificial enzymes with

287 k_{cat}/K_M values that are within the 10^3–10^6 M^{-1} s^{-1} range encompassing a majority of natural

288 enzymes[27], and only 4- or 10-fold lower than those of the most active variants evolved from these

289   enzyme prototypes (e.g., k_{cat}/K_M of 126,000 M^{-1} s^{-1} and 53,100 M^{-1} s^{-1} for HG3.17[14] and KE70

290   R8 12/12B[10], respectively). To achieve these results, we tested a number of variants that is several

291   orders of magnitude lower than those previously used to achieve comparable improvements by

292   directed evolution[8,10]. Further increases to catalytic efficiency could be achieved by incorporating

293   beneficial mutations outside the active site, which have been shown to augment catalysis via

294   alterations to allosteric networks[28]. Although more challenging to predict a priori, mutational

295   hotspots distal from the active site can be identified using nuclear magnetic resonance

296   spectroscopy[29] or by applying correlation-based tools to molecular dynamics trajectories[30]. In

297   theory, it should be possible to create artificial enzymes for any desired reaction with catalytic

298   efficiencies comparable to that of the average natural enzyme[27] using purely rational approaches,

299   and the ensemble-based design procedure described here can expedite this process.

300   The success of our ensemble-based design relied on exploiting the spatiotemporally-

301   averaged information contained in X-ray crystallographic data to overcome the backbone sampling

302   challenge that is responsible for much inaccuracy in enzyme design[8]. While others have previously

303   attempted to address the backbone sampling issue by using ensembles generated via Monte-Carlo-

304   based backrub sampling and incorporating loop remodelling during the enzyme design process,

305   activity improvements were modest (<5-fold)[10]. These results, in combination with our previous

306   observation that use of an ensemble generated by unconstrained molecular dynamics does not

307   allow accurate recapitulation of catalytic contact and active-site configurations for an efficient

308   artificial enzyme[14], suggest that to obtain large activity increases, it is not sufficient to introduce

309   backbone flexibility in the design process. Instead, the correct backbone conformation must be

310   sampled. Crystallographic ensemble refinement of the initial *de novo* enzyme satisfies this

311   stringent requirement in that the resulting model represents the true conformational ensemble

14

312   sampled by the enzyme, which should include productive substates that are better suited for

313   stabilization of the transition state than the average crystal structure. Generating the ensemble from

314   a structure with a bound transition-state analogue likely helps to enrich such productive substates,

315   and could partially explain why the KE70 ensemble, which was derived from an unbound

316   structure, led to a lower overall activity improvement. Although the use of an ensemble derived

317   from enzymes in their bound and unbound forms led to activity improvements, one important

318   disadvantage of our approach is that it requires a crystal structure of the original *de novo* enzyme

319   to generate the ensemble. Since *de novo* enzymes are typically generated from small, monomeric

320   protein scaffolds whose crystal structures have been determined to high resolution, we do not

321   anticipate that structure determination will create a substantial bottleneck in most cases.

322   Our results support the idea that to design efficient artificial enzymes, it is essential to

323   consider residual conformational heterogeneity present in the designs, and whether it leads to the

324   population of catalytically unproductive conformations. In other words, dynamic aspects of

325   enzyme structure, such as active-site preorganization and enrichment of catalytically-competent

326   substates, must also be considered. This is supported by the fact that the most active designs

327   described here, HG630 and HG649, were ranked lower than less active ones such as HG44 and

328   HG57 based on their predicted ability to stabilize the transition state (as reflected by computed

329   energies, Supplementary Table 2), which has hitherto been the most important metric used to pick

330   designs for experimental testing. Recently, researchers have proposed that enzyme design should

331   be viewed as a population shift problem, where relative stabilities of conformational substates are

332   redistributed by the introduction of mutations to stabilize productive substates[15,28]. Previous work

333   on the HG series of Kemp eliminases by our team[14] and others[15] demonstrated that directed

334   evolution improves activity through essentially the same mechanism, with higher activity variants

15

335   having reduced flexibility and greater active-site preorganization, both of which favor the

336   population of catalytically active substates. The similarity is further highlighted by the fact that

337   our ensemble-based design approach and directed evolution identify activity enhancing mutations

338   at many of the same positions.

339   Moving forward, it should be possible to further enhance the population of catalytically-

340   competent conformations for a designed enzyme ensemble using the information obtained from

341   ensemble refinement of X-ray diffraction data. Specifically, we anticipate using these ensembles

342   to identify sequences that can stabilize productive substates while simultaneously destabilizing

343   non-productive ones in a multistate design approach[31]. The ability to remodel an enzyme

344   conformational landscape[32] in this way, using negative design strategies to widen the energy gap

345   between productive and non-productive conformations, may open the door to the design of more

346   efficient artificial enzymes than previously possible. Beyond the scope of enzyme design, we

347   expect that a similar strategy, which takes advantage of crystallographically-derived ensemble

348   models, could find utility in a broad range of protein design applications. For example, directed

349   evolution following computational design of protein-protein interactions has been shown to

350   enhance affinity by eliminating conformations from the ensemble that are non-productive for

351   binding[24]. Additionally, conformational heterogeneity has been shown to be detrimental to the

352   functions of computationally designed fluorescent proteins[33] and ligand-binding proteins[34]. Each

353   of these observations suggests a potential application of our proposed approach.

354

355   **Methods**

356   *Ensemble generation.* Ensembles of backbone templates were generated using the ensemble

357   refinement protocol[18] implemented in the PHENIX macromolecular structure determination

358   software (v1.18.2-3874)[35]. In ensemble refinement, local atomic fluctuations are sampled using

359   molecular dynamics simulations accelerated and restrained by electron density to produce

360   ensemble models fitted to diffraction data. Briefly, input crystal structures were edited to remove

361   low-occupancy conformers and assign an occupancy of 1.0 to the remaining conformer. Following

362   addition of riding hydrogens, parallel ensemble refinement simulations were performed using

363   various combinations of the parameters p_{TLS} (0.6, 0.8, 0.9, 1.0), τ_x (0.5, 1.5, 2.0) and $w_{x\text{-}ray}$ (2.5,

364   5.0, 10.0), where p_{TLS} describes the percentage of atoms included in a translation-libration-screw

365   (TLS) model use to remove the effects of global disorder, τ_x is the simulation time-step and $w_{x\text{-}ray}$

366   is the coupled tbath offset, which controls the extent to which the electron density contributes to

367   the simulation force field such that the simulation runs at a target temperature of 300 K. The

368   ensemble generated from each crystal structure that displayed the lowest R_{free} value was selected

369   for design and analysis (Supplementary Table 1).

370

371   *Computational enzyme design.* All calculations were performed with the Triad protein design

372   software[36] (Protabit, Pasadena, CA, USA) using a Monte Carlo with simulated annealing search

373   algorithm for rotamer optimization. Individual backbone templates from each structural ensemble

374   were prepared for computational design using the *addH.py* application within Triad, which

375   optimized and renamed hydrogen atoms, assigned protonation state to His residues, flipped

376   His/Asn/Gln sidechains if necessary, and rotated hydroxyl, sulfhydryl, methyl, and amino groups

377   in Ser/Thr, Cys, Met, and Lys, respectively.

378   The Kemp elimination transition-state (TS) was built using parameters described by Privett

379   and coworkers[7]. For HG3 designs, D127 was used as the catalytic base, and Gln/Asn/Thr/ Ser were

380   tested as hydrogen-bond donors at various positions (Supplementary Table 7). For KE70 designs,

17

381   D16 served as the catalytic base (corresponding to position 17 in the KE70 crystal structure, PDB

382   ID: 3NPV), Q138 as hydrogen-bond donor, and F48 was utilized for introduction of a pi-stacking

383   interaction with the TS (Supplementary Table 9). For both HG3 and KE70 designs, all other

384   positions in the active site were mutated to Gly during theozyme placement to avoid steric clashes

385   with designed catalytic residues. The 2002 Dunbrack backbone-independent rotamer library[37] with

386   expansions of $\pm$ 1 standard deviation around χ_1 and χ_2 was used to provide side-chain

387   conformations. A library of TS poses was generated in the active site by targeted ligand placement[1]

388   using the contact geometries listed in Supplementary Table 10. TS pose energies were calculated

389   using a modified version of the Phoenix protein design energy function[36] consisting of a Lennard-

390   Jones 12–6 van der Waals term from the Dreiding II force field[38] with atomic radii scaled by 0.9,

391   a direction-dependent hydrogen bond term with a well depth of 8.0 kcal mol^{-1} and an equilibrium

392   donor-acceptor distance of 2.8 Å[39], and an electrostatic energy term modeled using Coulomb's law

393   with a distance-dependent dielectric of 10. During the energy calculation step, TS–side-chain

394   interaction energies were biased to favor interactions that satisfy contact geometries

395   (Supplementary Table 11) by applying an energy benefit of -100 kcal mol^{-1} as described by Lassila

396   *et al.*[1]. A Triad patch file for theozyme placement is provided as a Supplementary File.

397   Next, active-site repacking calculations were performed on the theozyme-containing

398   templates. In these calculations, the TS was translated $\pm$ 0.4 Å in each Cartesian coordinate in 0.2-

399   Å increments and rotated 10° about all three axes (origin at TS geometric center) in 5° increments

400   for a total combinatorial rotation/translation search space of 15,625 possible poses. The identities

401   of catalytic residues were fixed and allowed to sample all rotamers of that amino-acid type.

402   Residues that were converted to Gly in the theozyme placement step were allowed to sample

403   rotamers of selected amino acids (Supplementary Tables 7 and 9) to form a mostly hydrophobic

404   active site. Side-chain–TS interaction energies were biased to favor contacts satisfying geometries

405   as done during the theozyme placement step (Supplementary Table 11). Rotamer optimization was

406   carried out using the search algorithm, rotamer library, and energy function described above. A

407   Triad patch file for active-site repacking is provided as a Supplementary File.

408   After active-site repacking, we calculated energy differences between each repacked

409   structure and the corresponding structure in the absence of the TS where all designed residues

410   (including catalytic residues) were converted to Gly. This energy subtraction was done to allow

411   comparison of energies for sequences across multiple backbone templates. We also measured

412   angles defining the hydrogen-bond contact between the catalytic base and the TS of the top-scoring

413   sequence obtained from each backbone template. Sequences from the HG3 and KE70 backbone

414   template that gave the lowest energy top-ranked sequence with angles between its catalytic base

415   and the transition state within 3% or 3.5% error of the optimal geometries calculated for acetamide

416   dimers[23] (Supplementary Figure 2, Supplementary Table 3), respectively, were selected for library

417   design and cleaning, as described below.

418

419   *Computational library design*. Library design was performed with the CLEARSS algorithm[40]

420   using the energies obtained after active-site repacking on the single template selected as described

421   above. For a specific library size configuration, which is the specific number of amino acids at

422   each position in the protein, the highest probability set of amino acids at each position (based on

423   the sum of their Boltzmann weights) were included in the library. A combinatorial library of

424   approximately 1000 sequences derived from the selected HG3 or KE70 ensemble member was

425   generated. To ensure that the lowest energy rotameric configuration was obtained for each library

426   sequence, we used the *cleanSequences.py* app in Triad to "clean" their structures by optimizing

427   rotamers on the input backbone template using the active-site repacking protocol described above

428   but without modification of catalytic residue rotameric configuration. To compare energies of

429   "cleaned" sequences, we calculated the energy difference between each optimized structure and

430   the corresponding structure in the absence of the TS where all designed residues (including

431   catalytic residues) were converted to Gly. These energies are reported throughout the figures and

432   text.

433

434   *Design filtering.* To decrease the number of sequences to test experimentally, "cleaned" structures

435   were filtered using geometrical criteria. We kept sequences with (i) a TS solvent-accessible surface

436   area lower than 100 Å^2 or 102 Å^2 for HG3 and KE70 designs, respectively, and (ii) $\geq$70 % of all

437   designed active-site residues predicted to be preorganized, which was determined as those that

438   adopted the same rotamer in the absence and presence of TS. Furthermore, sequences that

439   contained $\geq$5 Met residues or $\geq$2 Cys residues were discarded to reduce conformational

440   heterogeneity of the active site and prevent formation of disulfide bonds, respectively. A final

441   filtering step consisting of short molecular dynamics simulations was performed for HG3 designs,

442   as described below.

443

444   *Unconstrained molecular dynamics simulation for filtering of HG3 designs.* All simulations were

445   performed using the Amber 2020 software (http://ambermd.org/) with the AMBER19SB

446   forcefield[41]. Long-range electrostatics (>10 Å) were modeled using the particle mesh Ewald

447   method[42], and a time step of 2 fs was used for the production phase. Parameters for the 5-

448   nitrobenzisoxazole substrate were generated using the Antechamber[43] package. "Cleaned"

449   computational models generated by Triad for the 55 sequences that passed the filtering procedure

450 described above were prepared for molecular dynamics. The TS structure was converted to that of

451 the substrate, hydrogen atoms were added using Reduce[44], and each substrate-bound protein

452 molecule was placed in a dodecahedral box with periodic boundary conditions where the distance

453 between the protein surface and the box edges were set to 10 Å. After explicit TIP3P water

454 molecules[45] were added, charges on protein atoms were neutralized with Na^+ and Cl^- counter-ions

455 at a concentration of 0.15 M. The structures were then energy minimized with the steepest descent

456 method to a target maximum force of 1000 kJ mol^{-1} nm^{-1}. Before equilibration, the system was

457 heated to a target temperature of 300 K for 100 ps. The system was then equilibrated under an

458 NVT ensemble for 100 ps at a temperature of 300 K using a Nose-Hoover thermostat[46], while

459 applying position restraints for heavy protein atoms. A second equilibration step under an NPT

460 ensemble was performed for 100 ps with constant pressure and temperature of 1 bar and 300 K,

461 respectively, using the Berendsen barostat[47]. Following removal of position restraints, 20-ns

462 production runs under Parrinello-Rahman pressure coupling[48] were initiated from the final

463 snapshot of the NPT equilibration. After molecular dynamics, designs were evaluated and ranked

464 according to their catalytic competency, which is the percentage of snapshots in which catalytic

465 contacts between substrate and catalytic side chains were maintained, as calculated using distance

466 and angle metrics listed on Supplementary Figure 3.

467

468 *Protein expression and purification.* Codon-optimized (*E. coli*) and his-tagged (C-terminus) genes

469 for Kemp eliminases (Supplementary Tables 12–13, Supplementary Figures 7–8) cloned into the

470 pET-29b(+) vector via *Nde*I and *Xho*I were obtained from Twist Bioscience. Enzymes were

471 expressed in *E. coli* BL21-Gold (DE3) cells (Agilent) using lysogeny broth (LB) supplemented

472 with 100 µg mL^{-1} kanamycin. Cultures were grown at 37 °C with shaking to an optical density at

473   600 nm of 0.3–0.7, and protein expression was initiated with 1 mM isopropyl-β-D-1-

474   thiogalactopyranoside. Following incubation at 16 °C for 16 h with shaking (250 rpm), cells were

475   harvested by centrifugation, resuspended in 8 mL lysis buffer (5 mM imidazole in 100 mM

476   potassium phosphate buffer pH 8.0) supplemented with 1.25 g mL^{-1} of lyophilized lysozyme and

477   1 U mL^{-1} of benzonase nuclease (Merck Millipore), and lysed with an EmulsiFlex-B15 cell

478   disruptor (Avestin). Proteins were purified by immobilized metal affinity chromatography using

479   Ni–NTA agarose (Qiagen) pre-equilibrated with lysis buffer in individual Econo-Pac gravity-flow

480   columns (Bio-Rad). Columns were washed twice, first with 10 mM imidazole in 100 mM

481   potassium phosphate buffer (pH 8.0), and then with the same buffer containing 20 mM imidazole.

482   Bound proteins were eluted with 250 mM imidazole in 100 mM potassium phosphate buffer (pH

483   8.0) and exchanged into 100 mM sodium phosphate buffer (pH 7.0) supplemented with 100 mM

484   sodium chloride using Econo-Pac 10DG desalting pre-packed gravity-flow columns (Bio-Rad).

485   Proteins used for crystallization were further purified by gel filtration in 50 mM sodium citrate

486   buffer (pH 5.5) and 150 mM sodium chloride using an ENrich SEC 650 size-exclusion

487   chromatography column (Bio-Rad). Purified samples were concentrated using Amicon Ultracel-

488   3K centrifugal filter units (EMD Millipore) and quantified by measuring the absorbance of the

489   denatured protein in 6 M guanidinium chloride at 280 nm and applying Beer-Lambert's law using

490   calculated extinction coefficients obtained from the ExPAsy ProtParam tool

491   (https://web.expasy.org/protparam).

492

493   *Steady-state kinetics.* All assays were carried out at 27 °C in 100 mM sodium phosphate buffer

494   (pH 7.0) supplemented with 100 mM sodium chloride. Triplicate 200-µL reactions with varying

495   concentrations of freshly prepared 5-nitrobenzisoxazole (Aablocks) dissolved in methanol (10%

496   final concentration, pH of reaction mixture adjusted to 7.0 after addition of methanol-solubilized

497   substrate) were initiated by the addition of 0.02–5.0 µM or 0.03–16.0 µM for HG or KE70 variants,

498   respectively. Product formation was monitored spectrophotometrically at 380 nm ($\varepsilon = 15{,}800$ M^{-1}

499   cm^{-1}) in individual 96-well plates (Greiner Bio-One) wells using a Biotek Synergy H1 multimode

500   plate reader (Agilent). Path lengths for each well were calculated ratiometrically using the

501   difference in absorbance of 100 mM sodium phosphate buffer (pH 7.0) supplemented with 100

502   mM sodium chloride and 10% methanol at 900 and 975 nm (27 °C). Linear phases of the kinetic

503   traces were used to measure initial reaction rates. For cases where saturation was not possible at

504   the maximum substrate concentration tested (2 mM), data were fitted to the linear portion of the

505   Michaelis-Menten model ($v_0 = (k_{cat}/K_M)[E_0][S]$) and k_{cat}/K_M was deduced from the slope. In all

506   other cases, data were fitted to the Michaelis-Menten equation to calculate individual k_{cat} and K_M

507   parameters.

508

509   *Crystallization.* Enzyme variants were prepared in 50 mM sodium citrate buffer (pH 5.5) at the

510   concentrations listed in Supplementary Table 4. For samples that were co-crystallized with the

511   transition-state analogue, a 100 mM stock solution of 6-nitrobenzotriazole (6NT, AstaTech) was

512   prepared in dimethyl sulfoxide (DMSO) and diluted 20-fold in the enzyme solutions for a final

513   concentration of 5 mM (5% DMSO). For each enzyme variant, we carried out initial crystallization

514   trials in 15-well hanging drop format using EasyXtal crystallization plates (Qiagen) and a

515   crystallization screen that was designed to explore the chemical space around the crystallization

516   conditions reported by Broom *et al.*[14] Crystallization drops were prepared by mixing 1 µL of

517   protein solution with 1 µL of the mother liquor and sealing the drop inside a reservoir containing

518   an additional 500 µL of the mother liquor solution. This procedure was successful for HG185,

519 HG198, and HG630; however, crystallization of HG649 required identification of a new

520 crystallization condition using sparse matrix screening. We used commercial screening kits

521 (NeXtal) to prepare crystallization drops in 96-well sitting drop plates by mixing 1 μL of protein

522 solution with 1 μL of the mother liquor and sealing the drop inside a reservoir containing an

523 additional 100 μL of the mother liquor solution. After identifying a suitable mother liquor solution

524 from screening experiments, large crystals suitable for X-ray diffraction experiments were

525 obtained in 15-well hanging-drop format as described for the other HG variants. The specific

526 growth conditions that yielded the crystals of each HG variant used for X-ray data collection are

527 provided in Supplementary Table 4. HG185, HG630, and HG649 crystallized in the absence of

528 the 6NT transition-state analogue, and the resulting crystals were isomorphous with the HG3

529 crystal form reported in the PDB (PDB ID: 5RGA and 5RG4). For these variants, crystals with

530 bound 6NT were obtained by soaking the unbound crystals in mother liquor containing 10 mM

531 6NT for at least 30 minutes prior to data collection. On the other hand, HG198 could not be

532 crystallized without 6NT present, and the crystals that were obtained belonged to space group P1

533 with three polypeptides in the asymmetric unit. To prepare crystals of HG198 without 6NT bound,

534 we serially soaked 6NT-bound crystals in three drops of crystallization mother liquor without 6NT.

535 Each sequential soaking step was carried out for at least 30 minutes. After removal of 6NT by

536 soaking, the P1 crystals undergo a transition to space group $P2_1$, with a smaller unit cell and only

537 one molecule per asymmetric unit. Although we could not determine the cause of this unusual

538 change in crystal symmetry upon soaking, we observed that it occurred with high reproducibility.

539 We measured 10 individual crystals of 6NT-bound HG198, which all belonged to space group P1

540 and were roughly isomorphous. Additionally, we measured four individual crystals of HG198

541 without 6NT, and found that all of them demonstrated the transition to monoclinic symmetry.

542

X-ray data collection and processing. Prior to X-ray data collection, crystals were mounted in polyimide loops and sealed using a MicroRT tubing kit (MiTeGen). Single-crystal X-ray diffraction data were collected on beamline 8.3.1 at the Advanced Light Source. The beamline was equipped with a Pilatus3 S 6M detector, and was operated at a photon energy of 11111 eV. Crystals were maintained at 280 K throughout the course of data collection. Each data set was collected using a total X-ray dose of 50 kGy or less, and covered a 180° wedge of reciprocal space. Multiple data sets were collected for each enzyme variant either from different crystals, or if their size permitted, from non-overlapping volumes of larger crystals, in order to identify optimally diffracting samples. X-ray data were processed with the Xia2 0.5.492 program (https://doi.org/10.1107/S0021889809045701)[49], which performed indexing, integration, and scaling with DIALS[50], followed by merging with Pointless[51]. For each data set, a resolution cutoff was taken where the CC1/2 and $<I/\sigma I>$ values for the merged intensities fell to approximately 0.5 and 1.0, respectively. Information regarding data collection and processing is presented in Supplementary Table 5. The reduced diffraction data were analyzed with phenix.xtriage to check for crystal pathologies, and no complications were identified.

558

Structure determination. We obtained initial phase information for calculation of electron density maps by molecular replacement using the program Phaser[52], as implemented in v1.13.2998 of the PHENIX suite[53]. Several different models of HG variants, including crystal structures and design models, were used for molecular replacement. For all data sets except that of HG630 (+) 6NT, we performed iterative steps of manual model rebuilding followed by refinement of atomic positions, atomic displacement parameters, and occupancies using a translation-libration-screw (TLS)

565 model, a riding hydrogen model, and automatic weight optimization. For HG630 (+) 6NT,

566 refinement was done as described above but without usage of a translation-libration-screw (TLS)

567 model. All model building was performed using Coot 0.8.9.236[54] and refinement steps were

568 performed with phenix.refine within the PHENIX suite (v1.13-2998)[53,55]. Restraints for 6NT were

569 generated using phenix.elbow[56], starting from coordinates available in the Protein Data Bank (PDB

570 ligand ID: 6NT). Further information regarding model building and refinement, as well as PDB

571 accession codes for the final models, are presented in Supplementary Table 5.

572

Data availability

574 Structure coordinates for all HG-series Kemp eliminases have been deposited in the RCSB Protein

575 Data Bank with the following accession codes: HG185 (8USK, 8USL), HG198 (8USI, 8USJ),

576 HG630 (8USG, 8USH), HG649 (8USE, 8USF). Source data are provided with this paper. Other

577 relevant data are available from the corresponding authors upon reasonable request.

578

Code availability

580 Triad patch files are provided with this paper. Requests for the Triad protein design software

581 should be addressed to Protabit (https://www.protabit.com/).

582

Acknowledgements

599

Author Contributions

601   R.V.R., M.C.T. and R.A.C. conceived the project. R.V.R. and N.Z. performed computational

602   design experiments. R.V.R. and J.D.M.M. purified proteins. R.V.R. and J.D.M.M. performed

603   enzyme kinetics experiments. B.S. crystallized proteins. J.M.R. and M.C.T. performed X-ray

604   diffraction experiments. B.S., R.V.R., and R.A.C. performed refinements. M.C.T. designed X-ray

605   crystallography experiments. R.A.C. and R.V.R. wrote the manuscript. N.Z., B.S., and M.C.T.

606   edited the manuscript.

607

Competing Interests

609   The authors declare no competing interests.

610

611

27

References

(1)   Lassila, J. K.; Privett, H. K.; Allen, B. D.; Mayo, S. L. Combinatorial methods for small-molecule placement in computational enzyme design *Proc Natl Acad Sci U S A* **103**,16710-16715 (**2006**).

(2)   Zanghellini, A.; Jiang, L.; Wollacott, A. M.; Cheng, G.; Meiler, J.; Althoff, E. A.; Rothlisberger, D.; Baker, D. New algorithms and an in silico benchmark for computational enzyme design *Protein Sci* **15**,2785-2794 (**2006**).

(3)   Rothlisberger, D.; Khersonsky, O.; Wollacott, A. M.; Jiang, L.; DeChancie, J.; Betker, J.; Gallaher, J. L.; Althoff, E. A.; Zanghellini, A.; Dym, O.; Albeck, S.; Houk, K. N.; Tawfik, D. S.; Baker, D. Kemp elimination catalysts by computational enzyme design *Nature* **453**,190-195 (**2008**).

(4)   Jiang, L.; Althoff, E. A.; Clemente, F. R.; Doyle, L.; Röthlisberger, D.; Zanghellini, A.; Gallaher, J. L.; Betker, J. L.; Tanaka, F.; Barbas, C. F., 3rd; Hilvert, D.; Houk, K. N.; Stoddard, B. L.; Baker, D. De novo computational design of retro-aldol enzymes *Science* **319**,1387-1391 (**2008**).

(5)   Siegel, J. B.; Zanghellini, A.; Lovick, H. M.; Kiss, G.; Lambert, A. R.; St Clair, J. L.; Gallaher, J. L.; Hilvert, D.; Gelb, M. H.; Stoddard, B. L.; Houk, K. N.; Michael, F. E.; Baker, D. Computational design of an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction *Science* **329**,309-313 (**2010**).

(6)   Bjelic, S.; Nivón, L. G.; Çelebi-Ölçüm, N.; Kiss, G.; Rosewall, C. F.; Lovick, H. M.; Ingalls, E. L.; Gallaher, J. L.; Seetharaman, J.; Lew, S.; Montelione, G. T.; Hunt, J. F.; Michael, F. E.; Houk, K. N.; Baker, D. Computational design of enone-binding proteins with catalytic activity for the Morita-Baylis-Hillman reaction *ACS Chem Biol* **8**,749-757 (**2013**).

(7)   Privett, H. K.; Kiss, G.; Lee, T. M.; Blomberg, R.; Chica, R. A.; Thomas, L. M.; Hilvert, D.; Houk, K. N.; Mayo, S. L. Iterative approach to computational enzyme design *Proc Natl Acad Sci U S A* **109**,3790-3795 (**2012**).

(8)   Blomberg, R.; Kries, H.; Pinkas, D. M.; Mittl, P. R.; Grutter, M. G.; Privett, H. K.; Mayo, S. L.; Hilvert, D. Precision is essential for efficient catalysis in an evolved Kemp eliminase *Nature* **503**,418-421 (**2013**).

(9)   Yeh, A. H.; Norn, C.; Kipnis, Y.; Tischer, D.; Pellock, S. J.; Evans, D.; Ma, P.; Lee, G. R.; Zhang, J. Z.; Anishchenko, I.; Coventry, B.; Cao, L.; Dauparas, J.; Halabiya, S.; DeWitt, M.; Carter, L.; Houk, K. N.; Baker, D. De novo design of luciferases using deep learning *Nature* **614**,774-780 (**2023**).

(10)   Khersonsky, O.; Rothlisberger, D.; Wollacott, A. M.; Murphy, P.; Dym, O.; Albeck, S.; Kiss, G.; Houk, K. N.; Baker, D.; Tawfik, D. S. Optimization of the in-silico-designed kemp eliminase KE70 by computational design and directed evolution *J Mol Biol* **407**,391-412 (**2011**).

(11)   Khersonsky, O.; Kiss, G.; Rothlisberger, D.; Dym, O.; Albeck, S.; Houk, K. N.; Baker, D.; Tawfik, D. S. Bridging the gaps in design methodologies by evolutionary optimization of the stability and proficiency of designed Kemp eliminase KE59 *Proc Natl Acad Sci U S A* **109**,10358-10363 (**2012**).

(12)   Giger, L.; Caner, S.; Obexer, R.; Kast, P.; Baker, D.; Ban, N.; Hilvert, D. Evolution of a designed retro-aldolase leads to complete active site remodeling *Nat Chem Biol* **9**,494-498 (**2013**).

657   (13)   Obexer, R.; Godina, A.; Garrabou, X.; Mittl, P. R.; Baker, D.; Griffiths, A. D.;
658   Hilvert, D. Emergence of a catalytic tetrad during evolution of a highly active artificial aldolase
659   *Nat Chem* **9**,50-56 (**2017**).
660   (14)   Broom, A.; Rakotoharisoa, R. V.; Thompson, M. C.; Zarifi, N.; Nguyen, E.;
661   Mukhametzhanov, N.; Liu, L.; Fraser, J. S.; Chica, R. A. Ensemble-based enzyme design can
662   recapitulate the effects of laboratory directed evolution in silico *Nat Commun* **11**,4808 (**2020**).
663   (15)   Otten, R.; Padua, R. A. P.; Bunzel, H. A.; Nguyen, V.; Pitsawong, W.; Patterson,
664   M.; Sui, S.; Perry, S. L.; Cohen, A. E.; Hilvert, D.; Kern, D. How directed evolution reshapes the
665   energy landscape in an enzyme to boost catalysis *Science* **370**,1442-1446 (**2020**).
666   (16)   Campbell, E.; Kaltenbach, M.; Correy, G. J.; Carr, P. D.; Porebski, B. T.;
667   Livingstone, E. K.; Afriat-Jurnou, L.; Buckle, A. M.; Weik, M.; Hollfelder, F.; Tokuriki, N.;
668   Jackson, C. J. The role of protein dynamics in the evolution of new enzyme function *Nat Chem*
669   *Biol* **12**,944-950 (**2016**).
670   (17)   Bunzel, H. A.; Anderson, J. L. R.; Hilvert, D.; Arcus, V. L.; van der Kamp, M.
671   W.; Mulholland, A. J. Evolution of dynamical networks enhances catalysis in a designer enzyme
672   *Nature Chemistry* **13**,1017-1022 (**2021**).
673   (18)   Burnley, B. T.; Afonine, P. V.; Adams, P. D.; Gros, P. Modelling dynamics in
674   protein crystal structures by ensemble refinement *Elife* **1**,e00311 (**2012**).
675   (19)   Keedy, D. A.; Fraser, J. S.; van den Bedem, H. Exposing Hidden Alternative
676   Backbone Conformations in X-ray Crystallography Using qFit *PLoS Comput Biol* **11**,e1004507
677   (**2015**).
678   (20)   Levin, E. J.; Kondrashov, D. A.; Wesenberg, G. E.; Phillips, G. N., Jr. Ensemble
679   Refinement of Protein Crystal Structures: Validation and Application *Structure* **15**,1040-1052
680   (**2007**).
681   (21)   Thompson, M. C. Combining temperature perturbations with X-ray
682   crystallography to study dynamic macromolecules: A thorough discussion of experimental
683   methods *Methods Enzymol* **688**,255-305 (**2023**).
684   (22)   Keedy, D. A.; van den Bedem, H.; Sivak, D. A.; Petsko, G. A.; Ringe, D.; Wilson,
685   M. A.; Fraser, J. S. Crystal cryocooling distorts conformational heterogeneity in a model
686   Michaelis complex of DHFR *Structure* **22**,899-910 (**2014**).
687   (23)   Morozov, A. V.; Kortemme, T.; Tsemekhman, K.; Baker, D. Close agreement
688   between the orientation dependence of hydrogen bonds observed in protein structures and
689   quantum mechanical calculations *Proc Natl Acad Sci U S A* **101**,6946-6951 (**2004**).
690   (24)   Biel, J. T.; Thompson, M. C.; Cunningham, C. N.; Corn, J. E.; Fraser, J. S.
691   Flexibility and Design: Conformational Heterogeneity along the Evolutionary Trajectory of a
692   Redesigned Ubiquitin *Structure* **25**,739-749 e733 (**2017**).
693   (25)   Maria-Solano, M. A.; Serrano-Hervas, E.; Romero-Rivera, A.; Iglesias-
694   Fernandez, J.; Osuna, S. Role of conformational dynamics in the evolution of novel enzyme
695   function *Chem Commun (Camb)* **54**,6622-6634 (**2018**).
696   (26)   Yabukarski, F.; Doukov, T.; Pinney, M. M.; Biel, J. T.; Fraser, J. S.; Herschlag,
697   D. Ensemble-function relationships to dissect mechanisms of enzyme catalysis *Science Advances*
698   **8**,eabn7738 (**2022**).
699   (27)   Bar-Even, A.; Noor, E.; Savir, Y.; Liebermeister, W.; Davidi, D.; Tawfik, D. S.;
700   Milo, R. The moderately efficient enzyme: evolutionary and physicochemical trends shaping
701   enzyme parameters *Biochemistry* **50**,4402-4410 (**2011**).

29

(28)   Osuna, S. The challenge of predicting distal active site mutations in computational enzyme design *WIREs Computational Molecular Science* **11**,e1502 (**2021**).

(29)   Bhattacharya, S.; Margheritis, E. G.; Takahashi, K.; Kulesha, A.; D'Souza, A.; Kim, I.; Yoon, J. H.; Tame, J. R. H.; Volkov, A. N.; Makhlynets, O. V.; Korendovych, I. V. NMR-guided directed evolution *Nature* **610**,389-393 (**2022**).

(30)   Maria-Solano, M. A.; Kinateder, T.; Iglesias-Fernandez, J.; Sterner, R.; Osuna, S. In Silico Identification and Experimental Validation of Distal Activity-Enhancing Mutations in Tryptophan Synthase *Acs Catalysis* **11**,13733-13743 (**2021**).

(31)   Davey, J. A.; Chica, R. A. Multistate approaches in computational protein design *Protein Sci* **21**,1241-1252 (**2012**).

(32)   St-Jacques, A. D.; Rodriguez, J. M.; Eason, M. G.; Foster, S. M.; Khan, S. T.; Damry, A. M.; Goto, N. K.; Thompson, M. C.; Chica, R. A. Computational remodeling of an enzyme conformational landscape for altered substrate selectivity *Nat Commun* **14**,6058 (**2023**).

(33)   Legault, S.; Fraser-Halberg, D. P.; McAnelly, R. L.; Eason, M. G.; Thompson, M. C.; Chica, R. A. Generation of bright monomeric red fluorescent proteins via computational design of enhanced chromophore packing *Chemical Science* **13**,1408-1418 (**2022**).

(34)   Tinberg, C. E.; Khare, S. D.; Dou, J.; Doyle, L.; Nelson, J. W.; Schena, A.; Jankowski, W.; Kalodimos, C. G.; Johnsson, K.; Stoddard, B. L.; Baker, D. Computational design of ligand-binding proteins with high affinity and selectivity *Nature* **501**,212-216 (**2013**).

(35)   Liebschner, D.; Afonine, P. V.; Baker, M. L.; Bunkoczi, G.; Chen, V. B.; Croll, T. I.; Hintze, B.; Hung, L.-W.; Jain, S.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R. D.; Poon, B. K.; Prisant, M. G.; Read, R. J.; Richardson, J. S.; Richardson, D. C.; Sammito, M. D.; Sobolev, O. V.; Stockwell, D. H.; Terwilliger, T. C.; Urzhumtsev, A. G.; Videau, L. L.; Williams, C. J.; Adams, P. D. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix *Acta Crystallographica Section D* **75**,861-877 (**2019**).

(36)   Lee, F. S.; Anderson, A. G.; Olafson, B. D. Benchmarking TriadAb using targets from the second antibody modeling assessment *Protein Engineering, Design and Selection* **36**,gzad013 (**2023**).

(37)   Dunbrack, R. L., Jr. Rotamer libraries in the 21st century *Curr Opin Struct Biol* **12**,431-440 (**2002**).

(38)   Mayo, S. L.; Olafson, B. D.; Goddard, W. A. Dreiding - a Generic Force-Field for Molecular Simulations *Journal of Physical Chemistry* **94**,8897-8909 (**1990**).

(39)   Dahiyat, B. I.; Mayo, S. L. Probing the role of packing specificity in protein design *Proc Natl Acad Sci U S A* **94**,10172-10177 (**1997**).

(40)   Allen, B. D.; Nisthal, A.; Mayo, S. L. Experimental library screening demonstrates the successful application of computational protein design to large structural ensembles *Proc Natl Acad Sci U S A* **107**,19838-19843 (**2010**).

(41)   Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis, J. L.; Dror, R. O.; Shaw, D. E. Improved side-chain torsion potentials for the Amber ff99SB protein force field *Proteins* **78**,1950-1958 (**2010**).

(42)   Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems *The Journal of Chemical Physics* **98**,10089-10092 (**1993**).

(43)   Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations *Journal of Molecular Graphics and Modelling* **25**,247-260 (**2006**).

747   (44)   Word, J. M.; Lovell, S. C.; Richardson, J. S.; Richardson, D. C. Asparagine and
748 glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation *J Mol*
749 *Biol* **285**,1735-1747 (**1999**).
750   (45)   Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L.
751 Comparison of simple potential functions for simulating liquid water *The Journal of Chemical*
752 *Physics* **79**,926-935 (**1983**).
753   (46)   Evans, D. J.; Holian, B. L. The Nose–Hoover thermostat *The Journal of Chemical*
754 *Physics* **83**,4069-4074 (**1985**).
755   (47)   Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J.
756 R. Molecular dynamics with coupling to an external bath *The Journal of Chemical Physics*
757 **81**,3684-3690 (**1984**).
758   (48)   Parrinello, M.; Rahman, A. Polymorphic transitions in single crystals: A new
759 molecular dynamics method *Journal of Applied Physics* **52**,7182-7190 (**1981**).
760   (49)   Winter, G.; Lobley, C. M.; Prince, S. M. Decision making in xia2 *Acta*
761 *Crystallogr D Biol Crystallogr* **69**,1260-1273 (**2013**).
762   (50)   Winter, G.; Waterman, D. G.; Parkhurst, J. M.; Brewster, A. S.; Gildea, R. J.;
763 Gerstel, M.; Fuentes-Montero, L.; Vollmar, M.; Michels-Clark, T.; Young, I. D.; Sauter, N. K.;
764 Evans, G. DIALS: implementation and evaluation of a new integration package *Acta*
765 *Crystallographica Section D* **74**,85-97 (**2018**).
766   (51)   Evans, P. Scaling and assessment of data quality *Acta Crystallogr D Biol*
767 *Crystallogr* **62**,72-82 (**2006**).
768   (52)   McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L.
769 C.; Read, R. J. Phaser crystallographic software *J Appl Crystallogr* **40**,658-674 (**2007**).
770   (53)   Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols,
771 N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty,
772 N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart,
773 P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution
774 *Acta Crystallogr D Biol Crystallogr* **66**,213-221 (**2010**).
775   (54)   Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of
776 Coot *Acta Crystallogr D Biol Crystallogr* **66**,486-501 (**2010**).
777   (55)   Afonine, P. V.; Grosse-Kunstleve, R. W.; Echols, N.; Headd, J. J.; Moriarty, N.
778 W.; Mustyakimov, M.; Terwilliger, T. C.; Urzhumtsev, A.; Zwart, P. H.; Adams, P. D. Towards
779 automated crystallographic structure refinement with phenix.refine *Acta Crystallogr D Biol*
780 *Crystallogr* **68**,352-367 (**2012**).
781   (56)   Moriarty, N. W.; Grosse-Kunstleve, R. W.; Adams, P. D. electronic Ligand
782 Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint
783 generation *Acta Crystallogr D Biol Crystallogr* **65**,1074-1080 (**2009**).

784

785   **Table 1. Kinetic parameters of Kemp eliminases**

Enzyme	Mutations [a]	# Mutations [a]	k_{cat} (s^{-1}) [b]	K_M (mM) [b]	k_{cat}/K_M (M^{-1} s^{-1}) [b]	Relative k_{cat}/K_M
HG series – Controls						
HG3	–	–	N.D.	N.D.	125 ± 8 (146 ± 6) [c]	1
HG3.3b	V6I K50H M84C S89R Q90D A125N	6	N.D.	N.D.	3400 ± 700 (2200 ± 100) [c]	27
HG3-K50Q/M84C	K50Q M84C	2	N.D.	N.D.	4300 ± 300	34
HG3.7	V6I Q37K K50Q M84C S89R Q90H A125N	7	N.D.	N.D.	24000 ± 3000 (27000 ± 2000) [c]	192
HG series – Designs						
HG378	A21C K50Q Q90L A125V W275V	5	N.D.	N.D.	70 ± 5	0.6
HG57	A21C K50Q Q90L A125V	4	N.D.	N.D.	120 ± 8	1
HG44	A21C K50Q Q90F A125V	4	N.D.	N.D.	250 ± 10	2
HG603	K50Q Q90F A125V W275V	4	N.D.	N.D.	800 ± 10	6.4
HG493	K50Q Q90F A125T W275T	4	N.D.	N.D.	2100 ± 100	17
HG185	A21C K50Q Q90F A125T W275V	5	N.D.	N.D.	2300 ± 100	18
HG198	K50Q M84C A125T F267M	4	N.D.	N.D.	8000 ± 300	64
HG259	K50Q M84C Q90L A125T F267M	5	N.D.	N.D.	13000 ± 400	104
HG630	K50Q M84C A125T F267M W275V	5	N.D.	N.D.	15000 ± 500	120
Without MD filtering [d]						
HG649	K50Q M84C Q90F A125T F267M W275V	6	N.D.	N.D.	32000 ± 3000	256
KE70 series – Controls						
KE70	–	–	N.D.	N.D.	57 ± 3 (78 ± 14) [c]	1
KE70-S20a/A240a [e]	S20a A240a	2	N.D.	N.D.	150 ± 7	2.6
R2 7/12F	D23G, Y48F, D212E, H251Y	4	0.50 ± 0.01	1.00 ± 0.06	500 ± 30 (1330 ± 13) [c]	9
R4 8/5A [e]	S20a, K29N, Y48F, W72C, H166Y, K197N, A204V, G240a	8	3.0 ± 0.1	1.0 ± 0.1	3000 ± 300 (4380 ± 350) [c]	53
KE70 series – Designs [f]						
KE701 [e]	H16D S20a D45Q Y48F W72C G101S S138Q H166N V168A A204V A240a	11	0.040 ± 0.001	0.10 ± 0.02	400 ± 80	7
KE703 [e]	H16D S20a D45N Y48F W72C G101M S138Q H166N V168A A204V A240a	11	0.50 ± 0.01	0.20 ± 0.02	2500 ± 300	44
KE703b [e]	S20a Y48F W72V G101M S138Q H166N V168A A204V A240a	9	N.D.	N.D.	5500 ± 100	96

786   [a] Mutations are relative to the starting template (HG3 or KE70).
787   [b] Data represent the average of six to fifteen individual replicate measurements from two to five independent protein batches. N.D. indicates that
788   individual parameters K_M and k_{cat} could not be determined accurately because saturation was not possible at the maximum substrate concentration
789   tested (2 mM, Supplementary Figure 4 and Supplementary Figure 6), which is the substrate's solubility limit. In these cases, catalytic efficiencies
790   (k_{cat}/K_M) were calculated from the slope of the linear portion ([S] << K_M) of the Michaelis-Menten model ($v_0 = (k_{cat}/K_M)[E_0][S]$). Errors of
791   regression fitting, which represent the absolute measure of the typical distance that each data point falls from the regression line, are provided.
792   [c] Values in parentheses are from Broom *et al.* [14] (HG series), or Röthlisberger *et al.* [3] and Khersonsky *et al.* [10] (KE70 series).
793   [d] HG649 is one of the 55 designs that passed all filtering criteria prior to the final molecular dynamics (MD) step.
794   [e] These enzymes contain two insertions, S20a and A240a/G240a.
795   [f] The KE702 design was inactive.

Figures

Figure 1. Ensemble-based computational enzyme design. (a) This procedure requires as inputs one or more theozymes, which are combinations of catalytic groups arranged in a unique geometry to stabilize a transition state (TS), and a backbone ensemble that approximates the intrinsic flexibility of the target protein fold. The algorithm proceeds in two stages: placement of each theozyme onto every member of the backbone ensemble (bb1–3), followed by repacking of active-site residues to identify sequences (seq1–3) that can further stabilize the TS. During repacking, both the identity and conformation of designed active-site residues are allowed to vary, and the TS is rotated and translated to reduce steric clashes with repacked side chains. In this toy example, only the theozyme containing a Gln hydrogen-bond donor is shown for clarity. After active-site repacking, designs from a single theozyme/template combinations are selected based on energy (bold outline) and filtered using structural criteria. (b) Filtering of designs is performed to reproduce mechanisms known to contribute to efficient enzyme catalysis. Accepted designs are those that have (1) near-ideal contact geometries between the TS and catalytic side chains (dashed lines), (2) active sites with high structural complementarity to the TS, as calculated by low TS solvent-accessible surface area (SASA), (3) highly preorganized active sites with most designed residues predicted to adopt the same rotameric configuration in the presence (white/orange) and absence (magenta) of TS, and (4) enriched catalytically competent substates, which are snapshots that preserve catalytic contacts over the course of short molecular dynamics (MD) simulations.

Figure 2. Ensemble-based design vs. directed evolution. (a) Ensemble-based design yields catalytic efficiency improvements comparable to those achieved by directed evolution with a fraction of the experimental screening effort. Full and dashed lines show ensemble-based design and directed evolution trajectories, respectively. (b) Ensemble-based design identifies a majority of the mutation sites (spheres) found by directed evolution (4/6) but mutation combinations of designed (HG649) and evolved (HG3.7) enzymes are distinct, as these share only two mutations (K50Q and M84C). (c) Full and dashed lines show ensemble-based design and directed evolution trajectories, respectively. KE703b differs from KE703 by reversion of its D16/N45 residues to the H16/D45 catalytic dyad found in KE70 and its evolved variants. (d) Designed variant KE703b shares 6 of the 9 mutation sites (spheres) found by directed evolution but has only three mutations in common with evolved variant R4 8/5A (S20a, Y48F, A204V).

Figure 3. Crystal structures of HG-series Kemp eliminases. In all cases, only atoms from chain A are shown. Structures of HG3 (PDB ID: 5RG4 and 5RGA) and its evolved variant HG3.7 (PDB ID: 5RG6 and 5RGC) were previously published[14]. (a) Hydrogen bonds to the 6-benzotriazole (6NT) transition-state analogue are shown as dashed lines and distances are indicated. The red sphere represents a water molecule. The 2Fo-Fc map is shown in volume representation at two contour levels: 0.5 eÅ^{-3} and 1.5 eÅ^{-3} in light and dark blue, respectively. In the case of HG185, occupancy of 6NT in the crystal is approximately 60%, which is reflected by its lower electron density. (b) Cut-away view shows that active sites of designs are more complementary to the transition-state analogue than that of the HG3 template, as indicated by lower solvent-accessible surface areas for 6NT (mean ± s.d. across all chains). 6NT is shown as spheres. (c) Superposition of the 6NT-bound structure (white) with the highest (magenta) and lowest (green) occupancy conformers of the unbound structure for each Kemp eliminase. Active-site residues that are not preorganized are indicated by an asterisk. In the starting template HG3 and evolved variant HG3.7, the unbound state is never preorganized for catalysis as both W44 and M237 in the major and minor conformer, respectively, adopt side-chain rotamers that would prevent productive binding of the transition state. In the HG185 design, C21 is never preorganized in the unbound state, and the catalytic base D127 is only preorganized in the major conformer (80% occupancy). In the HG198, HG630 and HG649 designs, only M237 adopts a non-productive conformation in the unbound state, with an occupancy ranging from 47 to 64%. (d) Ensemble refinement of 6NT-bound structures show that designed variants HG198, HG630 and HG649, as well as evolved variant HG3.7, display lower structural heterogeneity than HG3 and a higher percentage of ensemble members whose catalytic side chains (D127 and Q50) make hydrogen bonds with 6NT. In the case of HG185, the lower occupancy of 6NT in the crystal (approximately 60%) likely contributes to its comparable heterogeneity to HG3 and lower percentage of ensemble members making catalytic contacts with 6NT.

35

Figure 4. Ensemble-based design accurately predicts crystal structures of designed enzymes. Crystal structures of HG-series Kemp eliminases with bound 6NT (white) are overlaid on the corresponding design models obtained by ensemble-based design (blue). For clarity, only the major conformer of Chain A is shown. The transition state (TS) and transition-state analogue are shown at the center of each image. Side chains of all residues forming the binding pocket are shown with the exception of P45, which was omitted for clarity. The sphere shows the alpha carbon of G83. Asterisks indicate residues that adopt side-chain rotamers varying by >20 degrees around one or more side-chain dihedrals between the design model and crystal structure.

Figure 5. Enrichment of catalytically-competent substates in the conformational ensemble. Distributions of pairwise backbone root-mean-square deviations (RMSD) for designed active-site residues (listed in Supplementary Table 7) calculated between each backbone template obtained by ensemble refinement of various HG-series Kemp eliminases with bound 6NT and (a) each template within the same ensemble, (b) the bb05 template used for computational design, and (c) the HG3 crystal structure with bound 6NT (PDB ID: 5RGA[14]). Distributions show that (a) with the exception of HG185, ensemble members are more similar to each other in the ensembles of higher activity variants than in the ensemble of HG3, (b) the bb05 template is equally or more similar to the ensembles of the highest activity variants HG630 and HG649 (blue) than to its own ensemble (white), whereas (c) the HG3 crystal structure is more similar to its own ensemble (white) than to those from higher activity HG variants (blue). Median RMSD values and Z-scores for comparison of distributions are reported on Supplementary Table 6.